Clofarabine

Drug Profile

Clofarabine

Alternative Names: CAFdA; Cl-F-ara-A; Clofaribine; Clolar; Evoltra; GZ393590; JC0707; SAR 393590

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Southern Research Institute
  • Developer Bioenvision; Dana-Farber Cancer Institute; Erasmus MC; Genzyme Corporation; Genzyme Oncology; Massachusetts General Hospital; Oncology Specialists S.C.; Sanofi Genzyme; Sanofi Oncology; University of Michigan Comprehensive Cancer Center; Yale University
  • Class Antineoplastics; Purine nucleosides; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Acute lymphoblastic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia
  • Phase II Histiocytosis
  • Phase I/II Haematological malignancies
  • Preregistration Submission Withdrawal Acute myeloid leukaemia
  • Discontinued B cell lymphoma; Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Psoriasis; Solid tumours

Most Recent Events

  • 26 Mar 2017 Massachusettes General Hospital terminates a phase I/II trial in Non-Hodgkin lymphoma (Second-line therapy of greater) in USA due to discontinuation of drug formulation by Genzyme (NCT00644189)
  • 09 Jan 2017 Phase I/II development is ongoing in Haematological malignancies (Second-line therapy or greater, Combination therapy, In neonates, In infants, In children, In adolescents, In adults) in USA
  • 01 Dec 2016 Sanofi completes the phase I REFLEX trial for Haematological malignancies (Second line therapy or greater, Combination therapy, In neonates, In infants, In children, In adolescents, In adults) in USA (NCT00824135)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top